Future scope: the next decade.
Each projection is calibrated against working-group charters, draft documents, inspection patterns and conference outputs. Absence of signal means LOW confidence by definition.
Future scope · 2026–2035.
Projections · confidence calibrated to public signalsEach projection is calibrated against working-group charters, draft documents, inspection patterns and conference outputs. Absence of signal means LOW confidence by definition.
Virtual BE as supportive evidence watch.
Watch area for selected complex generics. Near-term use is more credible as supportive model-informed evidence; any move toward reduced in vivo evidence should be treated as product-specific and dependent on current regulator guidance or dialogue.
Long-acting injectable BE frameworks.
Late-2020s watch area. Long-acting injectables and depot products are likely to keep pushing product-specific guidance, steady-state designs, modelling, and release-rate evidence, but exact timelines should not be treated as official regulatory commitments.
Complex generic frameworks.
Peptides, suspensions, and drug-device combinations remain high-complexity areas. Product-specific precedents and patent-expiry pressure may drive more guidance, but convergence should be treated as uncertain until official documents appear.
Drug-device BE bridge.
Device interchangeability becomes a regulatory question (patient hand-feel of generic inhaler). FDA orally-inhaled guidance under continuing revision. EU MDR Article 117 notified-body bottleneck easing but still ~12-month review vs. 45-day medicinal-product timeline.
Biosimilar interchangeability.
Watch area through the late 2020s. Biosimilar interchangeability and substitution policy remain jurisdiction-specific; public claims should separate scientific comparability, legal interchangeability, and local substitution practice.
ANVISA-ICH biowaiver operationalisation.
Brazil-specific operationalisation should be tracked from official ANVISA updates and implementation practice. Persistent design questions include comparator sourcing, volunteer controls, documentation expectations, and biowaiver evidence packages.
HRMS bioanalytical baseline.
High-resolution MS is an analytical capability to watch where specificity or complex analytes matter. Any move into formal BE expectation should be tied to validated methods and current bioanalytical guidance, not assumed from technology maturity alone.
Microsampling standard.
DBS and VAMS remain case-by-case bioanalytical strategies. Population studies, paediatrics, and decentralised operations may increase interest, but matrix effects, validation, and bridging evidence remain the control points.
Genomic-stratified BE.
Genotype-aware BE designs are a horizon topic. They are technically plausible for selected questions, but public interpretation should avoid implying near-term routine regulatory use.
RWE for post-approval BE.
Real-world evidence may inform post-approval questions and safety or utilisation context, but it should not be presented as an established replacement for pivotal BE evidence.
Official source register.
Regulator / ICH anchorsICH M13A bioequivalence guideline.
Official FDA-hosted page for ICH M13A on bioequivalence for immediate-release solid oral dosage forms. Use as the first harmonised anchor for conventional oral IR BE framing.
BCS-based biowaiver guidance.
Official ICH M9 Step 4 guideline. Use for BCS classification, solubility/permeability thinking, and eligible biowaiver conditions.
Bioanalytical method validation and study sample analysis.
Official ICH M10 Step 4 guideline. Use for the bioanalytical evidence layer that supports BA/BE concentration data.
Product-specific guidances for generic development.
FDA product-specific guidance collection. Use before protocol lock because product-level recommendations can change design, fed/fasted, analyte, and BE expectations.
US bioavailability and bioequivalence regulation.
Electronic Code of Federal Regulations anchor for US BA/BE definitions and requirements. Use for statutory/regulatory context, not as a complete study-design manual.
Guideline on the investigation of bioequivalence.
EMA scientific guideline landing page for BE investigation. Use for EU framing, while checking product-specific or updated procedural context where relevant.
Multisource generic products and interchangeability.
WHO IRIS record for multisource pharmaceutical product guidance. Use as a WHO anchor for generic interchangeability and BE expectations in broader access settings.